Laruparetigene Zovaparvovec is a gene therapy commercialized by Applied Genetic Technologies, with a leading Phase II program in Retinitis Pigmentosa (Retinitis). According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Laruparetigene Zovaparvovec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Laruparetigene Zovaparvovec is expected to reach an annual total of $120 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Laruparetigene Zovaparvovec Overview
Laruparetigene zovaparvovec (AGTC-501) is under development for the treatment of X-linked retinitis pigmentosa (XLRP). It is administered through subretinal injection and acts by targeting X-linked retinitis pigmentosa GTPase regulator (RPGR). The gene therapy is developed based on adeno-associated virus (AAV) vector technology platform.
Applied Genetic Technologies Overview
Applied Genetic Technologies (AGTC) is a pharmaceutical company. The company Invovled in development of eye disease cures. AGTC develops treatments for patients that have diseases caused by broken genes. It offers products such X-linked retinitis pigmentosa, achromatopsia, bionic sight, age-related macular degeneration,non-syndromic hearing loss and deafness,frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company’s achromatopsia provides treatment for inherited conditions that are associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and total loss of color discrimination. AGTC’s x-linked retinoschisis offers treatment in retinal degeneration affecting young males, presenting with poor vision by school age. The company also offers ophthalmology development programs and proof-of-concept data in multiple indications. AGTC is headquartered in Alachua, Florida, the US
For a complete picture of Laruparetigene Zovaparvovec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.